Sanofi to buy Bioverativ for $11.6bn

23-01-2018

Sanofi to buy Bioverativ for $11.6bn

blackjack3d / iStockphoto.com

Paris-based Sanofi has revealed plans to acquire Bioverativ, a US-based biotech company focused on haemophilia treatments.


Sanofi, Bioverativ, mergers & acquisitions, haemophilia, therapies, M&A, strategy, blood disorders

LSIPR